The FDA has cleared Lyell Immunopharma Inc's (NASDAQ: LYEL) Investigational New Drug (IND) application to initiate a Phase 1 trial for LYL132 in solid tumors.

• LYL132 is an investigational T-cell receptor (TCR) therapy for patients with solid tumors expressing New York esophageal squamous cell carcinoma 1 (NY-ESO-1).

• LYL132 incorporates Epi-R, Lyell's epigenetic reprogramming technology, and is under investigation as a potential next-generation enhancement to letetresgene autoleucel (lete-cel), a GlaxoSmithKline Plc (NYSE: GSK) TCR therapy targeting NY-ESO-1.

• "Clearance of the second IND incorporating Lyell's novel reprogramming technologies is another important milestone for Lyell, especially coming within a month of FDA clearance of an IND for LYL797, our lead CAR program," said Liz Homans, CEO of Lyell.

• The planned Phase 1 trial will assess LYL132 in patients with NY-ESO-1+ advanced synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS).

• Lyell will manufacture LYL132 in its LyFE Manufacturing Center, and GSK will conduct the Phase 1 trial.

• Price Action: LYEL shares are down 4.30% at $5.01 during the market session on the last check Monday.

See more from Benzinga

• Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients

• FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.